Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Open-label, Single-dose Phase 1 Clinical Study to Investigate the Absorption, Metabolism and Excretion of APG-2575 in Healthy Subjects After Oral Administration of 400 mg/200 µCi [14C] APG-2575 Solution

Next Previous
Trial Profile

A Single-center, Open-label, Single-dose Phase 1 Clinical Study to Investigate the Absorption, Metabolism and Excretion of APG-2575 in Healthy Subjects After Oral Administration of 400 mg/200 µCi [14C] APG-2575 Solution

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisaftoclax (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Gastrointestinal stromal tumours; Multiple myeloma; Myelodysplastic syndromes; Neuroblastoma; Non-small cell lung cancer; Solid tumours; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics
  • Sponsors Ascentage Pharma

Most Recent Events

  • 24 May 2023 Status changed from active, no longer recruiting to completed.
  • 03 Jan 2023 Status changed from recruiting to active, no longer recruiting.
  • 21 Sep 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top